Anticoagulation for Stroke Prevention and Recovery after ICH (ASPIRE)

Brief description of study

Survivors of intracerebral hemorrhage (ICH) who have atrial fibrillation (AF) are at high risk for subsequent ischemic stroke. An “ischemic” stroke is an injury to the brain caused by a blocked blood vessel supplying the brain. Atrial fibrillation is a common cause of ischemic stroke. In people with atrial fibrillation, blood clots can form in the heart. These clots can break free, travel to the brain, block a blood vessel, and cause a stroke. Blood thinners are the best way to decrease the risk of ischemic stroke in patients with atrial fibrillation. Apixaban (also known as Eliquis®) and aspirin are two types of blood thinner medications. This study will compare the effects of apixaban (also known as Eliquis®) with aspirin in patients with atrial fibrillation and a recent brain hemorrhage to see which is better in preventing strokes and death.


Clinical Study Identifier: s19-01397
ClinicalTrials.gov Identifier: NCT03907046
Principal Investigator: Jennifer A. Frontera.
Other Investigators: Koto Ishida, David E. Kahn, Laura Mary Catherine Ades, Brandon Giglio, Aaron S Lord.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.